Your browser doesn't support javascript.
loading
A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults.
Khandelwal, Pooja; Langenberg, Lucille; Luebbering, Nathan; Lake, Kelly E; Butcher, Abigail; Bota, Kylie; Ramos, Kristie N; Taggart, Cynthia; Choe, Hannah; Vasu, Sumithira; Teusink-Cross, Ashley; Koo, Jane; Wallace, Gregory; Romick-Rosendale, Lindsey; Watanabe-Chailland, Miki; Haslam, David B; Lane, Adam; Davies, Stella M.
Affiliation
  • Khandelwal P; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Langenberg L; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
  • Luebbering N; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Lake KE; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
  • Butcher A; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Bota K; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
  • Ramos KN; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Taggart C; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
  • Choe H; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Vasu S; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Teusink-Cross A; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
  • Koo J; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Wallace G; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
  • Romick-Rosendale L; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Watanabe-Chailland M; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
  • Haslam DB; Division of Hematology, The Ohio State Comprehensive Cancer Center, Columbus OH.
  • Lane A; Division of Hematology, The Ohio State Comprehensive Cancer Center, Columbus OH.
  • Davies SM; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Blood ; 143(12): 1181-1192, 2024 Mar 21.
Article in En | MEDLINE | ID: mdl-38227933
ABSTRACT
ABSTRACT Vitamin A plays a key role in the maintenance of gastrointestinal homeostasis and promotes a tolerogenic phenotype in tissue resident macrophages. We conducted a prospective randomized double-blinded placebo-controlled clinical trial in which 80 recipients of hematopoietic stem cell transplantation (HSCT) were randomized 11 to receive pretransplant high-dose vitamin A or placebo. A single oral dose of vitamin A of 4000 IU/kg, maximum 250 000 IU was given before conditioning. The primary end point was incidence of acute graft-versus-host disease (GVHD) at day +100. In an intent-to-treat analysis, incidence of acute GVHD was 12.5% in the vitamin A arm and 20% in the placebo arm (P = .5). Incidence of acute gastrointestinal (GI) GVHD was 2.5% in the vitamin A arm (P = .09) and 12.5% in the placebo arm at day +180. Incidence of chronic GVHD was 5% in the vitamin A arm and 15% in the placebo arm (P = .02) at 1 year. In an "as treated" analysis, cumulative incidence of acute GI GVHD at day +180 was 0% and 12.5% in recipients of vitamin A and placebo, respectively (P = .02), and cumulative incidence of chronic GVHD was 2.7% and 15% in recipients of vitamin A and placebo, respectively (P = .01). The only possibly attributable toxicity was asymptomatic grade 3 hyperbilirubinemia in 1 recipient of vitamin A at day +30, which self-resolved. Absolute CCR9+ CD8+ effector memory T cells, reflecting gut T-cell trafficking, were lower in the vitamin A arm at day +30 after HSCT (P = .01). Levels of serum amyloid A-1, a vitamin A transport protein with proinflammatory effects, were lower in the vitamin A arm. The vitamin A arm had lower interleukin-6 (IL-6), IL-8, and suppressor of tumorigenicity 2 levels and likely a more favorable gut microbiome and short chain fatty acids. Pre-HSCT oral vitamin A is inexpensive, has low toxicity, and reduces GVHD. This trial was registered at www.ClinicalTrials.gov as NCT03202849.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Graft vs Host Disease Type of study: Clinical_trials Limits: Adult / Child / Humans Language: En Journal: Blood Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Graft vs Host Disease Type of study: Clinical_trials Limits: Adult / Child / Humans Language: En Journal: Blood Year: 2024 Document type: Article